This is from a slide from a recent company presentation discussing the product and opportunity momentum. XYOSTEDTM PDUFA goal date 9/29/18 - Potential Q418 launch o Growth of Makena® auto injector in 2H18 o Potential FDA approval of Teva partnered product o Expect to add to pipeline strategic new proprietary drug/device R&D combination product in 2H18 o Alliance Business partnership with Pfizer for rescue pen Looks like ATRS is very undervalued with this series of triggers shown above. Also the imminent launch of the first epipen direct substituible injector.
XYOSTEDTM PDUFA goal date 9/29/18 - Potential Q418 launch The above is the testosterone product. FDA action expected in less than two weeks.
In about one week we will see if the testosterone shot gets FDA approval. They received a CRL last year and were able to confer with the FDA to provided needed information. If it gets approved it will contribute significant bucks to ATRS. Plus the TEVA launch of the Generic EpiPen from ATRS is imminent as well. A solid income stream is being created for ATRS. Good Luck!
The FDA should rule on XYOSTED this Friday or by Monday this week. It will be the most significant product revenue wise for ATRS. Good Luck to all........
The 3rd quarter report was fabulous! This company is on a roll with lots of growth in it's future. Great stock to invest in.
Xyosted become available for purchase today and the reps will be in the field within 2 to 3 weeks. Great news!
